- Home
- ACN vs AMGN Comparison
ACN vs AMGN Comparison
Compare ACN & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACN
- AMGN
- Stock Information
- Founded
- ACN 1989
- AMGN 1980
- Country
- ACN Ireland
- AMGN United States
- Employees
- ACN N/A
- AMGN N/A
- Industry
- ACN Business Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACN Consumer Discretionary
- AMGN Health Care
- Exchange
- ACN Nasdaq
- AMGN Nasdaq
- Market Cap
- ACN 154.2B
- AMGN 156.3B
- IPO Year
- ACN N/A
- AMGN N/A
- Fundamental
- Price
- ACN $247.01
- AMGN $296.47
- Analyst Decision
- ACN Buy
- AMGN Hold
- Analyst Count
- ACN 20
- AMGN 18
- Target Price
- ACN $356.40
- AMGN $319.33
- AVG Volume (30 Days)
- ACN 4.7M
- AMGN 2.1M
- Earning Date
- ACN 09-25-2025
- AMGN 08-05-2025
- Dividend Yield
- ACN 2.40%
- AMGN 3.21%
- EPS Growth
- ACN 15.02
- AMGN 110.88
- EPS
- ACN 12.56
- AMGN 12.23
- Revenue
- ACN $68,482,535,999.00
- AMGN $34,917,000,000.00
- Revenue This Year
- ACN $8.02
- AMGN $7.96
- Revenue Next Year
- ACN $5.45
- AMGN $1.70
- P/E Ratio
- ACN $19.66
- AMGN $24.24
- Revenue Growth
- ACN 6.21
- AMGN 12.88
- 52 Week Low
- ACN $236.67
- AMGN $253.30
- 52 Week High
- ACN $398.35
- AMGN $339.17
- Technical
- Relative Strength Index (RSI)
- ACN 32.65
- AMGN 53.09
- Support Level
- ACN $236.67
- AMGN $282.60
- Resistance Level
- ACN $246.73
- AMGN $291.74
- Average True Range (ATR)
- ACN 6.31
- AMGN 6.70
- MACD
- ACN -0.23
- AMGN -0.79
- Stochastic Oscillator
- ACN 24.45
- AMGN 61.96
About ACN Accenture plc (Ireland)
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.